PARP1 and breast cancer: Olaparib, a highly selective potent poly(ADP‐ribose) polymerase (PARP) inhibitor, that inhibits base excision repair and single‐strand DNA break (SSB) repair, has recently been approved for therapy of ovarian and breast cancer 16, 17, 18.